title: Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
abstract: OBJECTIVE
  To assess the effects of patient-controlled methylphenidate for cancer-related fatigue.
  
  
  METHODS
  In this prospective open study, 31 patients with advanced cancer and fatigue who scored >/= 4 on a scale of 0 to 10 received methylphenidate 5 mg by mouth every 2 hours as needed for 7 days (maximum, 20 mg/d). Multiple symptoms were assessed daily; the primary end point, fatigue, was measured using the 0 to 10 scale, and the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F) was performed at baseline, day 7, and day 28.
  
  
  RESULTS
  The following mean (+/- standard deviation) scores for 30 assessable patients improved significantly between baseline and day 7: fatigue (0 to 10 scale), 7.2 +/- 1.6 v 3.0 +/- 1.9 (P <.001); overall well-being (0 to 10 scale), 4.5 +/- 2.2 v 2.8 +/- 2.1 (P <.001); fatigue (FACIT-F) subscore, 17.5 +/- 11.3 v 34.7 +/- 10.0 (P <.001); functional well-being, 14.4 +/- 5.9 v 18.3 +/- 6.6 (P <.001); and physical well-being, 13.5 +/- 6.4 v 21.4 +/- 5.0 (P <.001). Anxiety, appetite, pain, nausea, depression, and drowsiness all improved significantly (P <.05). All patients took afternoon or evening doses, and 28 patients (93%) took three or more doses daily. All patients chose to continue taking methylphenidate after 7 days of treatment. No serious side effects were reported.
  
  
  CONCLUSIONS
  These preliminary results suggest that patient-controlled methylphenidate administration rapidly improved fatigue and other symptoms. Randomized controlled trials are justified.
authors.affiliation: Department of Palliative Care and Rehabilitation Medicine, The University of Texas M.D. Anderson Cancer Center, Unit 8, 1515 Holcombe Blvd, Houston, TX 77030, USA. ebruera@mdanderson.org
authors.forename: Eduardo
authors.initials: E
authors.lastname: Bruera
authors.forename: Larry
authors.initials: L
authors.lastname: Driver
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Barnes
authors.forename: Jie
authors.initials: J
authors.lastname: Willey
authors.forename: Loren
authors.initials: L
authors.lastname: Shen
authors.forename: J Lynn
authors.initials: JL
authors.lastname: Palmer
authors.forename: Carmelita
authors.initials: C
authors.lastname: Escalante
mesh_terms: D000328:Adult; D000368:Aged; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D005221:Fatigue / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D011446:Prospective Studies; D012646:Self Administration; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate